Drug Profile
Latanoprost punctal plug - Mati Therapeutics
Alternative Names: L-PPDSLatest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator QLT
- Developer Mati Therapeutics
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
Most Recent Events
- 22 Jul 2022 Phase II development is ongoing in USA and Canada (Ophthalmic) (Mati Therapeutics pipeline, July 2022)
- 01 Feb 2021 Mati Therapeutics acquires purchase of rights for Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics
- 25 Apr 2017 Mati Therapeutics has patent protection for Evolute® punctal plug delivery system in USA and major international countries